AR

Athimulam Ramesh

Active Director Director DIN 06544186
DIN 06544186 First appointment Sep 2014 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2014
Shareholding value •••• Premium profile

About Athimulam Ramesh

Data last updated:

Athimulam Ramesh is a Director at Vans Pharma Private Limited (since 2014). The company operates in Pharma. Vans Pharma Private Limited reported revenue of ₹21.46 Cr (FY 2024).

DIN 06544186
Primary Designation Director
Industry Pharma
First Appointment 08 Sep 2014
Oldest Company Age 12 yrs
Largest company Vans Pharma Private Limited · ₹21.46 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Vans Pharma Private Limited U51909TN2014PTC097259
Director08 Sep 20142014₹21.46 Cr (FY 2024)Active

Board colleagues of Athimulam Ramesh

Directorship timeline

Open interactive timeline →
Vans Pharma Private Limited
Premium access

Shareholding and investment profile for Athimulam Ramesh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Athimulam Ramesh

Athimulam Ramesh currently holds 1 directorship: Vans Pharma Private Limited (Director, since 08 Sep 2014, revenue ₹21.46 Cr (FY 2024)).

Athimulam Ramesh was first appointed on 08 Sep 2014 as Director at Vans Pharma Private Limited.

The current boards of Athimulam Ramesh's companies include Gopalsamy Shyamala Devi (Vans Pharma Private Limited), Sheelarani (Vans Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available